Research | Open | Published:
Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
Acta Neuropathologica Communicationsvolume 4, Article number: 82 (2016)
Neuromyelitis optica/spectrum disorder (NMO/SD) is a severe, inflammatory disease of the central nervous system (CNS). In the majority of patients, it is associated with the presence of pathogenic serum autoantibodies (the so-called NMO-IgGs) directed against the water channel aquaporin 4 (AQP4), and with the formation of large, astrocyte-destructive lesions in spinal cord and optic nerves. A large number of recent studies using optical coherence tomography (OCT) demonstrated that damage to optic nerves in NMO/SD is also associated with retinal injury, as evidenced by retinal nerve fiber layer (RNFL) thinning and microcystic inner nuclear layer abnormalities. These studies concluded that retinal injury in NMO/SD patients results from secondary neurodegeneration triggered by optic neuritis.
However, the eye also contains cells expressing AQP4, i.e., Müller cells and astrocytes in the retina, epithelial cells of the ciliary body, and epithelial cells of the iris, which raised the question whether the eye can also be a primary target in NMO/SD. Here, we addressed this point in experimental NMO/SD (ENMO) induced in Lewis rat by transfer of AQP4268–285-specific T cells and NMO-IgG.
We show that these animals show retinitis and subsequent dysfunction/damage of retinal axons and neurons, and that this pathology occurs independently of the action of NMO-IgG. We further show that in the retinae of ENMO animals Müller cell side branches lose AQP4 reactivity, while retinal astrocytes and Müller cell processes in the RNFL/ganglionic cell layers are spared. These changes only occur in the presence of both AQP4268–285-specific T cells and NMO-IgG.
Cumulatively, our data show that damage to retinal cells can be a primary event in NMO/SD.
Optic nerves and spinal cord are preferential targets of inflammation in NMO/SD, an astrocytopathic disease of the central nervous system (CNS) associated with the presence of pathogenic serum autoantibodies directed against AQP4 [1–3]. A large number of recent studies using optical coherence tomography (OCT) demonstrated that damage to optic nerves in NMO/SD is also associated with retinal injury . This finding raised the questions whether retinal injury in NMO/SD patients only results from secondary neurodegeneration triggered by optic neuritis, whether it may also be a consequence of retinal inflammation initiated by AQP4-specific T cells, and whether there is a contribution of pathogenic AQP4-specific antibodies to this process. These questions were especially important since AQP4, the target antigen for both, is expressed in the eye: by Müller cells and astrocytes in the retina , and by epithelial cells of the ciliary body and the iris . To address these points, we searched for ocular inflammation in experimental NMO/SD (ENMO).
Materials and methods
All animal experiments were approved by the Ethic Commission of the Medical University Vienna and performed with the license of the Austrian Ministery for Science and Research (GZ66.009/195-WF-V-3b/2015;GZ66.009/0241-WF/II/3b/2014). Lewis rats were obtained from Charles River Wiga (Sulzfeld, Germany), and were used at an age of 7–8 weeks. During the experiments, they were housed in the Decentral Facilities of the Institute for Biomedical Research (Medical University Vienna) under standardized conditions.
T cells and immunoglobulins used in transfer experiments
The T cells used were specific for rat AQP4268–285 (KAAQQTKGSYMEVEDNRS) which contains two overlapping epitopes for antigen presentation via RT1.BL: QQTKGSYME, and TKGSYMEVE, and were grown under culture conditions selecting the T-helper 1 subset of CD4+ T cells [7–9].
The plasmapheresates used as sources for NMO-IgG were termed NMO-IgG9, NMO-IgGV, and NMO-IgGS. NMO-IgG9 derived from a Japanese NMO/SD patient with optic neuritis only, NMO-IgGV from an Austrian NMO/SD patient with optic neuritis followed 5 months later by myelitis, and NMO-IgGS from a Swedish NMO/SD patient with repeated optic neuritis and myelitis, and with additional MS-typical brain lesions. NMO-IgG9 and NMO-IgGV were purified using Protein G Sepharose 4 Fast Flow (GE Healthcare Bio-Sciences, Pasching, Austria) according to the manufacturer’s instructions, and adjusted to a concentration of 10 mg/ml. NMO-IgGS was injected as plasmapheresate without further purification. The use of the plasmapherisates/NMO-IgG preparations for research was approved by the Ethics Committee of Tohoku University School of Medicine (No. 2007–327), by the Regional and National Ethical Committee of Sweden (2013/153-31 Linköping), and by the Ethics Committees of the Medical University of Vienna (No. 1005/2014).
As negative control (co-IgG), commercially available normal human IgG (Subcuvia™, Baxter, Vienna) was used, diluted with phosphate buffered saline (PBS) to an IgG concentration of 10 mg/ml prior to use.
Induction of ENMO and tissue preparation
ENMO was induced by intraperitoneal injection of 1x107 AQP4268–285-specific T cells on day 0, followed by intraperitoneal injection of NMO-IgG on day 4 or 5. A few animals received 3x106 AQP4268–285-specific T cells on day 0, followed by intraperitoneal injection of NMO-IgG on day 5. The animals were then killed 24–48 h later with CO2 and perfused with 4 % paraformaldehyde in phosphate-buffered saline. The eyes were dissected, immersed for another 18–24 h in PFA and embedded in paraffin for histological analysis.
Histological and immunohistochemical analysis
All stainings were done essentially as described [10, 11] using rabbit polyclonal antibodies against AQP4 (Sigma, Germany), rabbit polyclonal against glial fibrillary acidic protein (GFAP; from Dako, Denmark), rabbit polyclonal antibodies against CD3 (to stain T cells; NeoMarkers, Fremont, USA), rabbit polyclonal antibodies against nitric oxide synthetase II (AB16311; Merck Millipore, Darmstadt, Germany), the mouse monoclonal antibody ED1 (to stain macrophages and activated microglia; Serotec, Germany), the mouse monoclonal anti-glutamine synthetase antibody (BD Biosciences, San Jose, USA), anti-human immunoglobulin (biotinylated donkey; polyclonal; Amersham, UK), anti-complement C9 (rabbit polyclonal ), and mouse monoclonal antibodies against amyloid-beta precursor protein (APP; Merck Millipore, Massachusetts, USA).
Counting and statistics
Counting was performed manually at 100 ×, 200 × or 400 × magnification using a morphometric grid. One slide contained two sagittal sections of one eye and one coronal section of the contralateral eye of the same animal. For quantification of the number of T cells in the retina, ciliary body, and iris, the largest inflammatory lesion per slide was chosen for each animal studied, and counted at 100 × magnification. For quantification of the number of T cells in different layers of the retina, one representative inflammatory lesion per slide and animal was chosen and counted at 100 × magnification. For quantification of the number of T cells proximal or distal to the optic nerve T cells in the whole proximal or distal sagittal sections were counted. To determine the number of APP+ spheroids, the largest lesion with APP+ structures was counted in the retina, papilla, and in the center and periphery of the optic nerve, using a 400 × magnification.
Statistics were calculated with IBM SPSS Statistics 21. The Mann-Whitney (Wilcoxon) U test and student’s t-test were used for statistical analysis. For multiple comparison corrections Bonferroni and Bonferroni-Holm was used.
The anterior visual pathway in ENMO
In ENMO, brain lesions with AQP4 loss occur on a background of diffuse T cell infiltration, are found in many different sites and may hit structures of the anterior visual pathway, but do not specifically target them (Fig. 1). Also the optic nerves of ENMO rats contain many T cells, but astrocyte-destructive lesions are essentially absent (Fig. 1).
Intraocular T cells in ENMO
Transfer of AQP4268–285-specific T cells (with or without NMO-IgG) into Lewis rats led to T cell infiltrates in retina and ciliary body. However, only the retinal T cell infiltration remained statistically significant, when these rats were compared to their counterparts injected with antibodies only (Fig. 2). In the iris, there was no increase in T cell numbers after injection of AQP4268–285-specific T cells and NMO-IgG. In fact, T cell numbers were even statistically higher in animals injected with NMO-IgG only, and in NMO-IgG injected rats compared to the co IgG/PBS group. However, since the overall numbers of T cells at this site were very low, we did not further follow up this point.
Instead, we next only studied the retina in more detail. Since in these initial ocular studies, 3x106 AQP4268–285-specific T cells have been injected, which was not sufficient to induce retinitis in all experimental animals (Fig. 2), we used for all following experiments 1x107 AQP4268–285-specific T cells and NMO-IgG to induce ENMO, to have a more stable model for studying the consequences of T cell infiltration into the retina. We found, that retinal T cell distribution followed two different gradients. The first gradient was proximal - > distal of the papilla, with most retinal T cells and perivascular T cell clusters found in close vicinity to or within the optic nerve head (Fig. 3). The second gradient was an inside - > outside gradient of infiltration, in which the highest numbers of intraparenchymal and perivascular retinal T cells was seen in the nerve fiber/ganglion cell/inner plexiform layers, lower numbers in the outer plexiform and nuclear layers, and essentially no T cells in the layers of rods and cones (Fig. 3). Sometimes, this gradient was interrupted by rare areas of perivascular T cell infiltration at vessels crossing through several retinal layers, mostly involving the outer nuclear/inner plexiform/inner nuclear layers (Fig. 3). Rarely, we also saw T cells in retinal pigment epithelium and choroid, but did not follow this up further (data not shown).
In ENMO, AQP4-specific T cells cause axonal pathology predominantly in the retinal nerve fiber/ganglionic cell layer
In NMO/SD patients, thinning of the retinal nerve fiber and ganglion cell layers is considered a secondary consequence of optic neuritis . However, in EAE models, encephalitogenic T cells are able to directly cause transient and permanent injury of neurons, as revealed by the formation of axonal spheroids and end bulbs . Is there evidence for axonal injury in the retina of our ENMO animals? To address this question, we next searched for APP+ spheroids/end bulbs and iNOS+ myeloid cells at this site. We found inflammatory lesions with APP+ axonal spheroids/end bulbs in the retinal nerve fiber/ganglionic cell layer, and significantly more APP+ structures in retina and papilla than in the extra-ocular optic nerve. These pathological changes could be clearly ascribed to the action of AQP4268–285-specific T cells, since T cells triggered the formation of APP+ structures both in the presence and in the absence of NMO-IgG (Fig. 4). Retinal APP+ axonal spheroids/end bulbs co-localized with iNOS+ macrophages/microglia (Fig. 4).
In ENMO, RNFL astrocytes are spared and Müller cells are damaged
The healthy retina is protected from serum antibodies by the inner and outer blood–retinal barriers (BRB) (30), but these barriers can be opened by inflammatory T cells, allowing the entry of NMO-IgG. Could this cause antibody-mediated damage to AQP4-expressing retinal astrocytes or Müller cells?
To address this question, we first concentrated on the retinal nerve fiber/ganglionic cell layer containing most retinal astrocytes  and the terminal processes of Müller cells . We did not see any evidence for AQP4 loss or for the formation of astrocyte-destructive lesions in these layers (Table 1): There was only little leakage of serum proteins like rat and human IgG and complement at the retinal nerve fiber/ganglionic cell layer, and we did not see the accentuated surface staining of astrocytic or Müller cell processes indicative of IgG or complement deposition on these cells (Fig. 5).
Next, we concentrated on inflammatory lesions in the inner plexiform/inner nuclear/outer plexiform/outer nuclear layers, where leakage of complement proteins and of rat and human IgG was more severe than the leakage seen in the retinal nerve fiber/ganglionic cell layer (Fig. 5), and where NMO-IgG should primarily target Müller cells, which have their perikarya in the inner nuclear layer, their stem processes spanning throughout the entire thickness of the retina, and their side branches in the outer and inner plexiform layers [14, 15] (Fig. 5). We found lesions with AQP4 loss in the outer plexiform layer (Table 1). To make sure that the AQP4 loss in the INL/OPL/ONL area was not a pathological feature unique to one NMO-IgG only, we also tested NMO-IgG from different sources (NMO-IgGs, NMO-IgGV, or NMO-IgG9). We observed AQP4 loss with NMO-IgG preparations from different patients (Table 1). The loss of AQP4 reactivity in the OPL was not caused by a cellular displacement due to inflammatory infiltrates, since there was no accumulation of glutamine synthetase or of GFAP expressing cells/cellular processes in the perilesional area (Figs. 5 and 6). We also did not see any evidence for deposition of C9 or human IgG on the surface of Müller cell bodies or stem processes (Figs. 5 and 6). AQP4 loss was only seen in the presence of both AQP4268–285-specific T cells and NMO-IgG.
We show here that damage to retinal axons and neurons in ENMO can be a primary event provoked by the induction of inflammatory lesions. These pathological changes could be clearly ascribed to the action of AQP4268–285-specific T cells, since T cells triggered the formation of APP+ structures both in the presence and in the absence of NMO-IgG. We further show that in ENMO, Müller cell side branches in the outer plexiform layer lose AQP4 reactivity. This effect is only seen when AQP4268–285-specific T cells induced inflammatory lesions in the presence of NMO-IgG.
The induction of ocular inflammation is not a unique feature of AQP4268–285-specific T cells, but also occurs when sufficient numbers of activated T cells specific for other ocular antigens are found in the circulation. Examples are T cells specific for the astrocytic S100β protein , for myelin basic protein (MBP) [17–19] which is a component of myelinated nerve bundles in the iris , and for the retinal soluble antigen (S-Ag)  or the cellular retinaldehyde binding protein (CRALBP) .
In the inflamed retina, AQP4268–285-specific T cells are predominantly found both within the parenchyma and within perivascular cuffs in the optic nerve head and in the peripapillary retina, and display two gradients of cellular distribution: the first one proximal - > distal of the optic nerve head, and the second one from inner - > outer retinal layers. The proximal - > distal gradient can be explained by anatomical properties of the vasculature: T cells enter at postcapillary venules, capillaries from the surface of the papilla are in direct continuation with capillaries of the peripapillary retina , and the number of capillary layers decreases from four in the peripapillary inner retina to two and one in more centrifugally located inner retinal parts . The gradient from inner - > outer retinal layers reveals that the majority of T cells infiltrating the retina comes from the retinal vasculature which forms the inner blood-retina barrier . Interspersed into these gradients is a small population of T cells in close vicinity to blood vessels spanning through the different retinal layers. At least some of these cells might cross through the choroidal vasculature which comprises the outer blood-retina barrier [25, 26].
Retinal T cell infiltration causes axonal pathology in the RNFL and in the optic nerve head, as evidenced by the presence of APP+ axonal spheroids/end bulbs. In the RNFL, these structures were associated with iNOS+ activated microglia/macrophages, in line with a breakdown of the inner blood-retinal barrier by pro-inflammatory cytokines  and reactive oxygen and nitrogen species . Possibly, the unmyelinated phenotype of retinal axons renders them especially susceptible to the damaging action of reactive nitric oxide species. The numbers of lesions with axonal pathology per retinal section were too small (on average 0.3/retinal section) to warrant translation of axonal dysfunction/loss into a measurable thinning of the RNFL. In addition, the absence of a macula in rats  also precludes a recapitulation of the macular thinning observed in NMO/SD patients. In the papilla, APP+ axonal spheroids/end bulbs were not associated with iNOS+ microglia/macrophages. This could suggest either that axonal pathology was initiated more proximally to the neuronal cell body, i.e., in the retinal nerve fiber layer/ganglionic cell layer, or different ages of inflammatory lesions in papilla and retinal nerve fiber/ganglionic cell layer, since iNOS expression by microglia/macrophages is temporally restricted . We did not find APP+ axonal spheroids/end bulbs in the outer plexiform/inner nuclear layer, although there were lesions with iNOS+ cells at this site. On the one hand, this could be due to immunomodulatory mediators acting at the outer blood-retinal barrier, among them interleukin-10 and pigment epithelium-derived factor, which could skew myeloid cells towards higher phagocytic actions [25, 30]. On the other hand, the axons of horizontal/bipolar cells found at this site might be too short to form spheroids/end bulbs detectable by our staining technique. Hence, axonal dysfunction/loss in the RNFL is a primary outcome of ENMO, but not the only one.
Müller cell side branches in the outer plexiform layer lose AQP4 reactivity, while the terminal processes of Müller cells and astrocytes in the RNFL remain intact. The most likely explanation for this finding is the higher amount of leakage of IgG and complement at the outer blood-retina barrier than at the inner blood-retina barrier. The AQP4 loss of Müller cell side branches was not a consequence of complement-dependent (CDC) or of antibody dependent cellular cytotoxicity (ADCC), since there was no evidence for complement or immunoglobulin deposition on these cells. In this aspect, our observations in ENMO animals reflect recent findings in 3 retinae from NMO/SD autopsy cases, where Müller cells displayed a unique dynamics with scattered loss of AQP4 reactivity, and where the authors also concluded that the pathological process in the retina may not involve CDC or ADCC . We do not know yet whether the scattered loss of AQP4 reactivity on Müller cells is caused by internalization of antibody-loaded AQP4, or whether it reflects the response of these cells to inflammatory cytokines or to injury of retinal neurons. The local loss of AQP4 reactivity on Müller cell processes in the outer plexiform layer could render these cells more susceptible to osmotic stress without changing their expression levels of GFAP, in line with previous findings in AQP4 null mice [32, 33]. We also do not know yet how long the effects on Müller cells last – especially since we saw loss of AQP4 reactivity under conditions of T cell infiltration and microglia activation/macrophage recruitment, while the 3 human retinae described did not contain T cells or B cells . There is currently still some controversy about the role of T cells in NMO/SD. However, since T cells are found in early active lesions of NMO/SD patients [8, 34], and since AQP4-specific T cells are found in the normal immune repertoire of humans, and are expanded in the repertoire of NMO/SD patients [35–37], their possible contribution to retinal pathology in NMO/SD patients should not be ignored. Further studies are needed to specifically address this point.
Cumulatively, however, our pathological findings in the ENMO retina, and the recent study on NMO/SD retinae  come both to the same conclusion: Damage to the retina in NMO/SD may not only be caused by secondary retrograde changes after optic neuritis, but may also be a primary outcome of the disease.
We showed here that rats with ENMO developed retinitis, which was associated with two types of retinal damage: With the formation of APP+ axonal spheroids/end bulbs in retina and papilla which could be clearly ascribed to the action of AQP4268-285-specific T cells, and with the loss of AQP4 reactivity in Müller cell side branches in the outer plexiform layer which was only seen when AQP4268-285-specific T cells and NMO-IgG were present. Currently, it remains unclear whether such pathological changes also occur in the retina of NMO/SD patients. To address this issue, peripapillary retinae of these patients have to be studied at the peak of optic neuritis.
Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, Lassmann H, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol. 2012;3:58–73.
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7.
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12.
Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21:678–88. doi:10.1177/1352458514567216.
Nagelhus EA, Veruki ML, Torp R, Haug FM, Laake JH, Nielsen S, et al. Aquaporin-4 water channel protein in the rat retina and optic nerve: polarized expression in Muller cells and fibrous astrocytes. J Neurosci. 1998;18:2506–19.
Yamaguchi Y, Watanabe T, Hirakata A, Hida T. Localization and ontogeny of aquaporin-1 and −4 expression in iris and ciliary epithelial cells in rats. Cell Tissue Res. 2006;325:101–9.
Pohl M, Fischer MT, Mader S, Schanda K, Kitic M, Sharma R, et al. Pathogenic T cell responses against aquaporin 4. Acta Neuropathol. 2011;122:21–34. doi:10.1007/s00401-011-0824-0.
Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer MT, et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol Commun. 2013;1:85. doi:10.1186/2051-5960-1-85.
Zeka B, Hastermann M, Hochmeister S, Kogl N, Kaufmann N, Schanda K, et al. Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathol. 2015;130:783–98. doi:10.1007/s00401-015-1501-5.
Aboul-Enein F, Bauer J, Klein M, Schubart A, Flügel A, Ritter T, et al. Selective and antigen-dependent effects of myelin degeneration on central nervous system inflammation. J Neuropathol Exp Neurol. 2004;63:1284–96.
Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66:630–43. doi:10.1002/ana.21837.
Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol. 1993;143:555–64.
Aboul-Enein F, Weiser P, Hoftberger R, Lassmann H, Bradl M. Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis. Acta Neuropathol. 2006;111:539–47.
Watanabe T, Raff MC. Retinal astrocytes are immigrants from the optic nerve. Nature. 1988;332:834–7.
Reichenbach A, Bringmann A. New functions of Muller cells. Glia. 2013;61:651–78. doi:10.1002/glia.22477.
Kojima K, Wekerle H, Lassmann H, Berger T, Linington C. Induction of experimental autoimmune encephalomyelitis by CD4+ T cells specific for an astrocyte protein, S100 beta. J Neural Transm Suppl. 1997;49:43–51.
Adamus G, Amundson D, Vainiene M, Ariail K, Machnicki M, Weinberg A, et al. Myelin basic protein specific T-helper cells induce experimental anterior uveitis. J Neurosci Res. 1996;44:513–8.
Constantinescu CS, Lavi E. Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Curr Eye Res. 2000;20:71–6.
Verhagen C, Mor F, Cohen IR. T cell immunity to myelin basic protein induces anterior uveitis in Lewis rats. J Neuroimmunol. 1994;53:65–71.
Becker MD, Wiehler U, Miller DW. Vasculitis in multiple sclerosis. In: Gardner TW, Joussen AM, Kirchhof B, Ryan SJ, editors. Retinal vascular disease. Berlin: Springer; 2007. p. 650–6. ISBN 978-3-540-29542-6.
Wildner G, Thurau SR. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye. Eur J Immunol. 1995;25:1292–7.
Deeg CA, Raith AJ, Amann B, Crabb JW, Thurau SR, Hauck SM, et al. CRALBP is a highly prevalent autoantigen for human autoimmune uveitis. Clin Dev Immunol. 2007;2007:39245. doi:10.1155/2007/39245.
Hayreh SS. Blood supply of the optic nerve head and its role in optic atrophy, glaucoma, and oedema of the optic disc. Br J Ophthalmol. 1969;53:721–48.
Archer DB, Gardner TW, Stitt AW. Functional anatomy, fine structure and basic pathology of the retinal vasculature. In: Gardner TW, Joussen AM, Kirchhof B, Ryan SJ, editors. Retinal vascular disease. Berlin, Heidelberg, New York: Springer; 2007. p. 3–23. ISBN 978-3-540-29542-6.
Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat Rev Immunol. 2013;13:206–18. doi:10.1038/nri3391.
Cioffi GA, Granstam E, Alm A. Ocular circulation. In: AA Kaufman PL, editor. Adler’s physiology of the eye. 10th ed. St Louis: Mosby; 2003. p. 747–84. ISBN 0-323-01136-5.
Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, Peng B, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res. 1997;49:268–80.
Kerr EC, Copland DA, Dick AD, Nicholson LB. The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis. Prog Retin Eye Res. 2008;27:527–35. doi:10.1016/j.preteyeres.2008.07.001.
Huber G, Heynen S, Imsand C, vom Hagen F, Muehlfriedel R, Tanimoto N, et al. Novel rodent models for macular research. PLoS One. 2010;5:e13403. doi:10.1371/journal.pone.0013403.
Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009;182:4415–22. doi:10.4049/jimmunol.0713732.
Hokari M, Yokoseki A, Arakawa M, Saji E, Yanagawa K, Yanagimura F, et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol. 2016;79:605–24. doi:10.1002/ana.24608.
Pannicke T, Wurm A, Iandiev I, Hollborn M, Linnertz R, Binder DK, et al. Deletion of Aquaporin-4 renders retinal glial cells more susceptible to osmotic stress. J Neurosci Res. 2010;88:2877–88. doi:10.1002/jnr.22437.
Nicchia GP, Pisani F, Simone L, Cibelli A, Mola MG, Dal Monte M, et al. Glio-vascular modifications caused by aquaporin-4 deletion in the mouse retina. Exp Eye Res. 2016;146:259–68. doi:10.1016/j.exer.2016.03.019.
Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450–61.
Matsuya N, Komori M, Nomura K, Nakane S, Fukudome T, Goto H, et al. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol. 2011;23:565–73. doi:10.1093/intimm/dxr056.
Vaknin-Dembinsky A, Brill L, Kassis I, Petrou P, Ovadia H, Ben-Hur T, et al. T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO). Mult Scler Relat Disord. 2016;6:28–36. doi:10.1016/j.msard.2015.12.004.
Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72:53–64. doi:10.1002/ana.23651.
Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Amsterdam/Boston: Academic Press/Elsevier; 2007. ISBN-13: 978–0125476126.
Mueller T. What is the Thalamus in Zebrafish? Front Neurosci. 2012;6:64. doi:10.3389/fnins.2012.00064.
This work was supported by the Austrian Science Fund (grant numbers P25240-B24 and P28476-B30 to MB, by the Else Kröner-Fresenius-Stiftung (grant number 2013_A283 to MB), by the Austrian Ministery of Science, Research and Economy (BIGWIG-MS to HL and MR), and by Grants-in-aid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology of Japan to KF and TM. We thank Marianne Leisser, Ulrike Köck, and Angela Kury for excellent technical assistance.
BZ and MH established T cell lines and performed the animal experiments. BZ made all histological analysis. NK made the retinal preparations. KS purified the NMO-IgGs, MP contributed to analysis of the optic nerve head, TM, PR, KF, IN, CD, and FL provided the plasmapheresates, MR and HL provided intellectual input. MB designed the study and planned all experiments. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.